FDA Recommends Pause in Johnson & Johnson COVID-19 Vaccines Due to Blood Clots Cases

By  //  April 13, 2021

Share on Facebook Share on Twitter Share on LinkedIn Share on Delicious Digg This Stumble This

FDA recommends pause until review is completed

ABOVE VIDEO: FDA recommends pausing use of J&J vaccine due to rare side effect.

(FOX NEWS) – The Food and Drug Administration (FDA) together with the Centers for Disease Control and Prevention (CDC) is recommending a pause in the rollout of the Johnson & Johnson COVID-19 vaccine after several instances of severe blood clots in recipients.

According to the FDA, there have been six reported cases of the rare and severe type of blood clot in over 6.8 million Johnson & Johnson COVID-19 vaccine recipients.

“Right now, these adverse events appear to be extremely rare,” the agency said on Twitter. “Treatment of this specific type of blood clot is different from the treatment that might typically be administered. CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases.”

However, until that review is completed, the FDA is “recommending this pause.”

CLICK HERE TO READ FULL ARTICLE ON FOX NEWS

CLICK HERE FOR BREVARD COUNTY NEWS

Leave a Comment